Qu Biologics Introduces Travel Subsidy Program for Crohn's Clinical Trial Participants
(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 07/30/13 -- ., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the body's immune system, announced that it has received ethics approval to implement a program to help subsidize travel and hotel costs for participants of its .
"In response to participant interest from across Canada we felt it was important to offer a travel and hotel allowance to minimize any financial burden to participants of our Crohn's clinical trial," said Dr. Hal Gunn. "The travel subsidy program will be beneficial to participants already enrolled as well as those considering enrolling," Dr. Gunn commented.
Participants of Qu Biologics' Crohn's clinical trial living more than 150 kilometres from the trial site in downtown Vancouver, B.C. will be eligible to receive an allowance to help subsidize travel and hotel costs. Travel allowances will be paid out in three equal installments, one after each of the participant's three visits to the trial site. To learn more about the Qu Crohn's trial travel subsidy program, visit: .
About Qu Biologics
Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to reboot the body's immune system. SSIs are designed to stimulate an immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and autoimmune disease.
Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease; and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally. For more information, visit and .
Contacts:
Julie Jang
Director, Communications
Qu Biologics Inc.
604.734.1450 ext.41491
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 30.07.2013 - 16:00 Uhr
Sprache: Deutsch
News-ID 283098
Anzahl Zeichen: 0
contact information:
Town:
VANCOUVER, BRITISH COLUMBIA
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 238 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Qu Biologics Introduces Travel Subsidy Program for Crohn's Clinical Trial Participants"
steht unter der journalistisch-redaktionellen Verantwortung von
Qu Biologics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
